15 s stiff ode solver Search Results


hydroperoxy 5z 8z 11z 13e  (Avanti Polar)
91
Avanti Polar hydroperoxy 5z 8z 11z 13e
Hydroperoxy 5z 8z 11z 13e, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/15(S)-HETE/pmc05087874-290-26-9
Average 91 stars, based on 1 article reviews
hydroperoxy 5z 8z 11z 13e - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
source 15 s column  (Cytiva Europe)
95
Cytiva Europe source 15 s column
Source 15 S Column, supplied by Cytiva Europe, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/SOURCE+15S/pmc04957752-94-21-24
Average 95 stars, based on 1 article reviews
source 15 s column - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
5-s-hydroperoxy eicosatetraenoic acid 5(s)-hete  (Biomol GmbH)
90
Biomol GmbH 5-s-hydroperoxy eicosatetraenoic acid 5(s)-hete
5 S Hydroperoxy Eicosatetraenoic Acid 5(s) Hete, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/5+hydroxyeicosatetraenoic+acid++5+hete+/pmc02978721-177-6-21
Average 90 stars, based on 1 article reviews
5-s-hydroperoxy eicosatetraenoic acid 5(s)-hete - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
19(s)-hydroxyeicosatetraenoic acid (19(s)-hete  (Biomol GmbH)
90
Biomol GmbH 19(s)-hydroxyeicosatetraenoic acid (19(s)-hete
19(s) Hydroxyeicosatetraenoic Acid (19(s) Hete, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/12+s++hydroxyeicosatetraenoic+acid++12+s++hete+/pmc05861196-68-36-47
Average 90 stars, based on 1 article reviews
19(s)-hydroxyeicosatetraenoic acid (19(s)-hete - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
14c]15(s)-hete  (Biomol GmbH)
90
Biomol GmbH 14c]15(s)-hete
14c]15(s) Hete, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/14c+15+s++hete/10__1194_slash_jlr__m081448-55-1-12
Average 90 stars, based on 1 article reviews
14c]15(s)-hete - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tergitoltm 15 s 20  (Dow Chemical)
86
Dow Chemical tergitoltm 15 s 20
Tergitoltm 15 S 20, supplied by Dow Chemical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/12+15+s+tergitoltm/us12404351-45-20-29
Average 86 stars, based on 1 article reviews
tergitoltm 15 s 20 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
actigraph gt1m  (ActiGraph llc)
90
ActiGraph llc actigraph gt1m
Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 <t> s, ≤ 15 s, </t> raw data) and alphabetically within each epoch group
Actigraph Gt1m, supplied by ActiGraph llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/actigraph+gt3x/pmc09106641-25-38-37
Average 90 stars, based on 1 article reviews
actigraph gt1m - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
single lense reflex camera sony alpha 77ii  (Sony)
90
Sony single lense reflex camera sony alpha 77ii
Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 <t> s, ≤ 15 s, </t> raw data) and alphabetically within each epoch group
Single Lense Reflex Camera Sony Alpha 77ii, supplied by Sony, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/single+lense+reflex+camera+sony+alpha+77ii/10__1002_slash_pssb__201900755-204-31-30
Average 90 stars, based on 1 article reviews
single lense reflex camera sony alpha 77ii - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
s)-3-amino-3-(4-hydroxyphe- nyl)propionic acid [(s)- β-tyrosine  (PepTech Corporation)
90
PepTech Corporation s)-3-amino-3-(4-hydroxyphe- nyl)propionic acid [(s)- β-tyrosine
Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 <t> s, ≤ 15 s, </t> raw data) and alphabetically within each epoch group
S) 3 Amino 3 (4 Hydroxyphe Nyl)propionic Acid [(S) β Tyrosine, supplied by PepTech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/r++3+amino+4+phenyl+butyric+acid+hcl+salt/pmc06312381-58-1-25
Average 90 stars, based on 1 article reviews
s)-3-amino-3-(4-hydroxyphe- nyl)propionic acid [(s)- β-tyrosine - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
5(s),14(r),15(s)-trihydroxy-6trans -8- cis -10,12- trans -eicosatetraenoic acid (lxb 4)  (Biomol GmbH)
90
Biomol GmbH 5(s),14(r),15(s)-trihydroxy-6trans -8- cis -10,12- trans -eicosatetraenoic acid (lxb 4)
Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 <t> s, ≤ 15 s, </t> raw data) and alphabetically within each epoch group
5(s),14(r),15(s) Trihydroxy 6trans 8 Cis 10,12 Trans Eicosatetraenoic Acid (Lxb 4), supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/lxb4/10__1016_slash_s0022___2275_ascii40_20_ascii41_32129___5-76-26-39
Average 90 stars, based on 1 article reviews
5(s),14(r),15(s)-trihydroxy-6trans -8- cis -10,12- trans -eicosatetraenoic acid (lxb 4) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tergitoltm 15 s 9 (100)  (SERVA Electrophoresis)
90
SERVA Electrophoresis tergitoltm 15 s 9 (100)
Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 <t> s, ≤ 15 s, </t> raw data) and alphabetically within each epoch group
Tergitoltm 15 S 9 (100), supplied by SERVA Electrophoresis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/tergitoltm+15+s+9++100+/pmc11994376-56-0-6
Average 90 stars, based on 1 article reviews
tergitoltm 15 s 9 (100) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
actitrainer  (ActiGraph llc)
90
ActiGraph llc actitrainer
Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 <t> s, ≤ 15 s, </t> raw data) and alphabetically within each epoch group
Actitrainer, supplied by ActiGraph llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/15+s+stiff+ode+solver/actitrainer/pmc09106641-19-51-47
Average 90 stars, based on 1 article reviews
actitrainer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 s, ≤ 15 s, raw data) and alphabetically within each epoch group

Journal: Osteoporosis International

Article Title: A comparison of the associations between bone health and three different intensities of accelerometer-derived habitual physical activity in children and adolescents: a systematic review

doi: 10.1007/s00198-021-06218-5

Figure Lengend Snippet: Study characteristics, accelerometry methods used and the relationships reported between MPA and/or MVPA and VPA with measures of bone health in children and adolescents for the 30 reviewed studies. Studies are grouped and presented by imaging method and study type (cross-sectional or longitudinal/prospective) then by epoch length (≥ 60 s, ≤ 15 s, raw data) and alphabetically within each epoch group

Article Snippet: Tan et al. 2018 [ ] Cross-sectional ◆◆ , n = 101 (39/62) 15.4 ± 0.04 years Health Promoting Secondary Schools study Years post-APHV, 2.58 ± 0.76 years Girls’ age at menarche, 12.3 ± 1.2 years , Actigraph GT1M 15-s epoch Location: right iliac crest Worn for: 7 days (except WB activities) For inclusion: ≥ 3 days with ≥ 10 h Non-wear: log sheet recording wear 60 min consecutive 0 counts , MVPA, ≥ 2296 cpm VPA, ≥ 4012 cpm (min/day): MVPA , 49.6 ± 21.8 VPA , 19.5 ± 13.0 , pQCT (Stratec XCT3000) 8% tibia : BSI (mg 2 /mm 4 ), ToA (mm 2 ), ToD (mg/cm 3 ) 50% tibia : polar SSI (mm 3 ), ToA (mm 2 ), BAc (mm 2 ), medullary area (mm 2 ), BMDc (mg/cm 3 ) , Used multiple variable regression models to assess the relations between PA and bone outcomes (fully adjusted model controlled for sex, ethnicity, maturity offset, tibial length, lean mass and sedentary time) 8% site: Bone strength index: MVPA : B ( 95% CI ) = 13.9 (− 3.8, 31.7), β = 0.15, R 2 of total model = 0.51, p > 0.05; VPA : B ( 95% CI ) = 34.0 (6.9, 61.1), β = 0.22, R 2 of total model = 0.52, p < 0.05—explained 7% variance, p = 0.01 Total bone CSA: MVPA : B ( 95% CI ) = 0.61 (− 0.55, 1.78), β = 0.10, R 2 of total model = 0.55 p > 0.05; VPA : B ( 95% CI ) = 0.55 (− 1.28, 2.37), β = 0.05, R 2 of total model = 0.55, p > 0.05 Total bone density: MVPA : B ( 95% CI ) = 0.09 (− 0.42, 0.60), β = 0.04, R 2 of total model = 0.29 p > 0.05; VPA : B ( 95% CI ) = 0.45 (− 0.34, 1.24), β = 0.12, R 2 of total model = 0.30, p > 0.05 50% site: Polar SSI: MVPA: B ( 95% CI ) = 2.8 (0.3, 5.4), β = 0.15, R 2 of total model = 0.76, p < 0.05—explained 3% of the variance, p = 0.01; VPA: B ( 95% CI ) = 3.6 (− 0.4, 7.6), β = 0.11, R 2 of total model = 0.75, p > 0.05 Total bone CSA: MVPA: B ( 95% CI ) = 0.39 (− 0.05, 0.82), β = 0.79, R 2 of total model = 0.11, p > 0.05; VPA : B ( 95% CI ) = 0.42 (− 0.26, 1.11), β = 0.07, R 2 of total model = 0.78, p > 0.05 Cortical area: MVPA: B ( 95% CI ) = 0.24 (− 0.04, 0.52), β = 0.10, R 2 of total model = 0.79, p > 0.05; VPA: B ( 95% CI ) = 0.36 (− 0.08, 0.80), β = 0.09, R 2 of total model = 0.79, p > 0.05 Medullary area: MVPA : B ( 95% CI ) = 0.15 (− 0.17, 0.46), β = 0.09, R 2 of total model = 0.47, p > 0.05; VPA : B ( 95% CI ) = 0.06 (− 0.43, 0.56), β = 0.02, R 2 of total model = 0.46, p > 0.05 Cortical density: MVPA : B ( 95% CI ) = 0.01 (− 0.22, 0.24), β = 0.005, R 2 of total model = 0.76, p > 0.05 VPA : B ( 95% CI ) = 0.09 (− 0.26, 0.45), β = 0.03, R 2 of total model = 0.76, p > 0.05.

Techniques: Imaging, Software, Activity Assay, Transformation Assay, Control

A summary of the accelerometer data collection and processing methods used in all studies included in the review ( N = 30)

Journal: Osteoporosis International

Article Title: A comparison of the associations between bone health and three different intensities of accelerometer-derived habitual physical activity in children and adolescents: a systematic review

doi: 10.1007/s00198-021-06218-5

Figure Lengend Snippet: A summary of the accelerometer data collection and processing methods used in all studies included in the review ( N = 30)

Article Snippet: Tan et al. 2018 [ ] Cross-sectional ◆◆ , n = 101 (39/62) 15.4 ± 0.04 years Health Promoting Secondary Schools study Years post-APHV, 2.58 ± 0.76 years Girls’ age at menarche, 12.3 ± 1.2 years , Actigraph GT1M 15-s epoch Location: right iliac crest Worn for: 7 days (except WB activities) For inclusion: ≥ 3 days with ≥ 10 h Non-wear: log sheet recording wear 60 min consecutive 0 counts , MVPA, ≥ 2296 cpm VPA, ≥ 4012 cpm (min/day): MVPA , 49.6 ± 21.8 VPA , 19.5 ± 13.0 , pQCT (Stratec XCT3000) 8% tibia : BSI (mg 2 /mm 4 ), ToA (mm 2 ), ToD (mg/cm 3 ) 50% tibia : polar SSI (mm 3 ), ToA (mm 2 ), BAc (mm 2 ), medullary area (mm 2 ), BMDc (mg/cm 3 ) , Used multiple variable regression models to assess the relations between PA and bone outcomes (fully adjusted model controlled for sex, ethnicity, maturity offset, tibial length, lean mass and sedentary time) 8% site: Bone strength index: MVPA : B ( 95% CI ) = 13.9 (− 3.8, 31.7), β = 0.15, R 2 of total model = 0.51, p > 0.05; VPA : B ( 95% CI ) = 34.0 (6.9, 61.1), β = 0.22, R 2 of total model = 0.52, p < 0.05—explained 7% variance, p = 0.01 Total bone CSA: MVPA : B ( 95% CI ) = 0.61 (− 0.55, 1.78), β = 0.10, R 2 of total model = 0.55 p > 0.05; VPA : B ( 95% CI ) = 0.55 (− 1.28, 2.37), β = 0.05, R 2 of total model = 0.55, p > 0.05 Total bone density: MVPA : B ( 95% CI ) = 0.09 (− 0.42, 0.60), β = 0.04, R 2 of total model = 0.29 p > 0.05; VPA : B ( 95% CI ) = 0.45 (− 0.34, 1.24), β = 0.12, R 2 of total model = 0.30, p > 0.05 50% site: Polar SSI: MVPA: B ( 95% CI ) = 2.8 (0.3, 5.4), β = 0.15, R 2 of total model = 0.76, p < 0.05—explained 3% of the variance, p = 0.01; VPA: B ( 95% CI ) = 3.6 (− 0.4, 7.6), β = 0.11, R 2 of total model = 0.75, p > 0.05 Total bone CSA: MVPA: B ( 95% CI ) = 0.39 (− 0.05, 0.82), β = 0.79, R 2 of total model = 0.11, p > 0.05; VPA : B ( 95% CI ) = 0.42 (− 0.26, 1.11), β = 0.07, R 2 of total model = 0.78, p > 0.05 Cortical area: MVPA: B ( 95% CI ) = 0.24 (− 0.04, 0.52), β = 0.10, R 2 of total model = 0.79, p > 0.05; VPA: B ( 95% CI ) = 0.36 (− 0.08, 0.80), β = 0.09, R 2 of total model = 0.79, p > 0.05 Medullary area: MVPA : B ( 95% CI ) = 0.15 (− 0.17, 0.46), β = 0.09, R 2 of total model = 0.47, p > 0.05; VPA : B ( 95% CI ) = 0.06 (− 0.43, 0.56), β = 0.02, R 2 of total model = 0.46, p > 0.05 Cortical density: MVPA : B ( 95% CI ) = 0.01 (− 0.22, 0.24), β = 0.005, R 2 of total model = 0.76, p > 0.05 VPA : B ( 95% CI ) = 0.09 (− 0.26, 0.45), β = 0.03, R 2 of total model = 0.76, p > 0.05.

Techniques: Activity Assay, Derivative Assay